Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I cannot say how much the company will talk about the money they're bringing in before financials are revealed, but by the end of the year, I really believe the revenue will justify $1 or more. That said, on the weakness today I added some more, I hadn't planned to, but couldn't resist the bargain basement price.
Current financials are known to be loaded with debt, but by the time we reach second quarter, they will turn around, by fourth quarter the company will have grown dramatically, and while that costs money, they'll be bringing in more money than anyone can imagine.
Everyone with businesses that deal with the public, or where people need to work in reasonably close proximity to one another are looking into how they can better protect themselves. Our products provide the ideal protection, whether a unit is purchased, or a company that utilizes them will provide the service. I believe that many of the companies that currently provide cleaning services that currently don't have our equipment will be looking to add it in the very near future as businesses reopen.
Gary
Do you know if the Ryobi sprayer they're using is electrostatic, or just a good power sprayer. As I gather it, coverage is more complete if it's electrostatic like the room units we sell.
Gary
I certainly agree TLD is generally released as soon as everything comes together and they can write it up. Technical conferences will be where all the details will come out, then after they have, they can be shared with investors. I doubt if TLD will be much more than a few paragraphs long, it will give the highlights, but not the details.
Gary
In terms of time to $.20, I believe it's very possible to reach $.20 next month, so that would be faster than $.01 to $.10 which it didn't quite make at the high today, hopefully tomorrow.
I believe the real shocker will come with second and third quarter financial results, $1 is almost certain by 3rd quarter results, but if it comes after second quarters, you might be looking at $5 with third quarter, which will probably come in early November. People are not going to believe the kind of money that will be coming in from the U.K. as well as growing sales here practically anywhere you look.
Gary
As I understand it, it's up to PSTI to grant compassionate use if asked by those receiving it. The country it's being used in has to agree, in that we've had one in the U.S. I believe we have that agreement, then it's up to the Doctor administering it and patient, or their family, to want it. I'm sure there is paperwork, I know nothing about if any charges are involved, but I wouldn't be surprised if it's free.
I believe there are a number of hospitals here in the U.S. participating in clinical trials utilizing the drug. Diverting one or more doses to use in coronavirus shouldn't be a problem.
The biggest problem with compassionate use, or right to try, is that it's possible to be paid, but only if you're willing to provide a great deal of information on the cost of making the drug. Most companies won't do that to be paid the cost of making it, so they either don't participate, or give it away. Many don't participate in the program because of that. I believe they ought to price the products at some percentage of SOC treatment, I think far more companies would be willing to participate if that were the case.
Gary
I believe that if an Analyst were being honest, he might say $15 is a target for the company on initiating trials for coronavirus, but a multibillion dollar market cap should result from an approval. When it reaches $15 he can revise upward, but many analysts will move a stock to a hold rating when their target price is reached. If the stock goes to $150 they'll take credit for the gain, they said hold, not sell, even though they gave you new stocks they rated buys.
I hate analysts who don't look at the long term potential.
Gary
Our current market cap is under $200 million, is there anyone who doesn't believe it could be ten to fifty times that big on an approval for pneumonia in coronavirus.
Gary
I think you're speaking about ASCO, as of now TLD won't be done by ASCO and while I do believe they intended to have a large booth there, with a virtual conference I have no idea how that may be handled. I do not know if they submitted an abstract for ASCO, but the conference is a month before they told us TLD ought to be released.
I don't think SNO will decide what format the conference will take until at least Summer, though all indications seem to say the disease will be reoccurring by November, when the Conference is scheduled. Perhaps we'll have therapies that lessen the risk and permit such conferences to be held with some precautions.
I'm of the belief that PSTI's PLX-PAD will work on the pneumonia and other organ problems coronavirus victims are experiencing. I don't know that the FDA will move fast enough to approve it by then, but they achieve 20,000 doses from a single placenta, so if approved, I believe the supply will be adequate to treat all on or approaching the need for a ventilator.
Gary
PCTL is becoming a cash cow, people who look at financials don't see it, and won't for some time, but listen to what the company is saying. We know they have debt, but at the rate they're growing it won't be long before the debt is easily dealt with, but expansion to produce substantially more of both it's units, as well as the sanitizing fluid they're selling will deal with some funding.
I'd certainly like to have a greater understanding of what's happening in the U.K., we have a staff there, is the intent to build that into a production facility for the equipment they're going to install there, or will they be made here in the U.S. Either way the company makes money, it would just be nice to know more than we do right now.
No stock sets new highs virtually every day, while I still believe we'll ultimately be selling for dollars, perhaps in time double digit dollars, but there will be down days to as gains are retrenched before advancing to new highs. We nearly made a dime today, then gave up a little, hard to say where we'll close, but it's not hard to say what direction the trend is going.
Gary
That may be true for many, but the various cable networks have featured a lot of young, healthy people who've passed on due to the disease. Many of the people have been healthcare providers. I don't believe anyone can be certain they're not at risk.
To date I only know of one person who's died, and it's not someone I know personally, rather someone my daughter knew and was her age, in her 40's. Don't be fooled by cautions to elderly and immune compromized people, this is a risk to everyone.
We need our drug in trial, that's what it takes to gain approvals, though I'd still love to learn or hundreds to thousands getting it on a compassionate use basis.
Gary
I don't believe a PR is assured by any means, if they had a partner, and if that partner paid a milestone payment when the trial were unblinded, it would be PR'd as a material event. They will receive no funds for unblinding, or anything else they do, actually including the act of releasing TLD, but that's what TLD is, the release of a summary of what is seen when the trial is unblinded, as well as an assessment of the way forward.
I believe they should be submitting a placeholder Abstract for SNO which hopefully can be replaced by the TLD. At SNO I believe we'll get the comprehensive data for the trial.
Of course we don't know if SNO will be a live or virtual or live conference this year, but either way, a presentation is considered to be peer review, so after it the full data can be shared with investors.
Gary
Last evening I heard a report on other organs being damaged because of blood clotting reducing blood flow. Once again, it seems to me that PLX-PAD's benefits in CLI is to build blood flow, so once again it may be the ideal drug to benefit several organs, just not the pneumonia in the lungs.
They're starting to use blood thinners in patients, but that too has risks. I'm really of the belief that as more becomes know about both how coronavirus causes bodily harm, and how PLX-PAD achieves benefits, it may be about as perfect a match as is possible. I really believe the greatest benefit will come from it's use at the onset of pneumonia, if I'm right, a lot of patients would never need hospital care at all, the cost of the drug would be tiny when compared with the cost of hospitalizing a patient for even a few days, and far less than anyone requiring a ventilator.
If they're not going to flood the hospitals with patients getting the drug on a compassionate use basis, they need to get it into trials right away. One month into a trial I believe they'll see trends worthy of approval.
Gary
I'm not a technical expert and no nothing about what Athersys is doing, but I do believe in competition, so both should be tried, it may very well be found that together they work better than either alone.
I can understand why PSTI didn't start with pneumonia, though clearly their patents recognize it's possibilities. I believe the cost of a pneumonia trial would be extremely expensive as at least prior to coronavirus, most would recover. While it still kills many, I believe they're a tiny percentage of all who get it. With coronavirus, the death rate is far greater, especially for patients sick enough to require ventilators.
I'd like to see essentially two different trials, one with patients already on ventilators, the other on people thought to be perhaps a day or two away from needing a ventilator. Let's see if most on ventilators survive, something they're not doing now, and if those pre-ventilator improve without ever requiring the ventilator. If both of these prove out, the next step would be to try the drug on newly diagnosed pneumonia, and see if it prevents the need for hospitalization.
I've had pneumonia a few times in my life, but prior to leukemia it didn't require hospitalization. Post stem cells I was hospitalized, probably more because of a weakened immune system than the severity of the infection. I suspect that if PLX-PAD did the job, even for me the hospital might be replaced with a few trips to the Doctors office to verify that it was getting better.
In the middle of a pandemic, I believe that trials, or compassionate use should be tried with anything that both Doctors and patients, or the families, agree to try. I think that it's Doctors, or other scientists who should decide what the best candidates to try our, not politicians pushing something suggested to them. The more you try, the more the top candidates rise to the top. I believe we'll be up on top, Athersys may be too, I believe in giving Doctors many tools in their toolkit so they can choose what works best for their patients.
Gary
If we're successful in a pneumonia trial that reduces the threat of coronavirus, by Fall, when many experts seem to believe it will come on again, perhaps we can lessen our concern, knowing that most deaths can be prevented with our drug. I suspect that wearing masks will become routine until we have a vaccine that's proven effective. Most restaurants will either eliminate tables, or only fill every other one, maintaining distance will be stressed, eliminating things like parties and stadiums full of people, but perhaps some fans can attend games with spacing between seats, likewise in theaters.
Sanitation will be stressed, and if you're interested, have a look at what PCTL is doing, I believe their equipment, or something like it, will find a way into all sorts of things, well beyond the hospitals they're in.
As an immune compromised senior, I'd just like to feel safe going practically anywhere. I don't so we remain at home virtually all the time. Hopefully the likelihood of infection is dramatically reduced over the Summer, but even that is by no means certain. At this point I believe that people like myself's strategy for the year is survive it, hopefully prosper on our stocks, but wait for safer times when vaccines provide protection from coronavirus, and hopefully PLX-PAD is part of the SOC for treating pneumonia.
Gary
PCTL over time will become an income driven company, and the earnings will grow with each succeeding quarter to the point that no one will deny how high it can go. Frankly we know that Governors would like to open their State's ASAP. How much more confident would each of us be if we knew that at our gym someone was using an electrostatic sprayer with our product every few hours, or even once a day. How much better would you feel about going into a store, a restaurant, getting into any transportation vehicle outside your own car, how about going on a cruise. In short, the potential to grow is really unlimited.
Can our device totally eliminate becoming infected, absolutely not, but it's routine use can certainly lessen the likelihood of being infected. It won't be free, the retailers can't add to their cost of doing business to give us the protection, but the cost shouldn't be that high based on the numbers of customers, but it's something that we as customers should let businesses know is we're willing to pay a little more for that protection.
Gary
Frankly, if we initiate an FDA approved trial I also hope we can maintain permitting compassionate use, or right to try, if a Doctor and family of the patient want it, and they aren't considered for the trial. I would hope that all who volunteer for the trial get the drug, more than sufficient people won't be getting the drug, so they can be the control.
As was just pointed out, we only know of 7 who received the drug, we also know that Germany is permitted to use it, but we have no idea if, or how many they may have dosed. Nor do we have any update from Israel as to whether they've expanded the use to many more under compassionate use.
Ours is not a treatment for coronavirus, it's a treatment for pneumonia, which is probably the reason for most coronavirus deaths. The good news is, as coronavirus goes away, which eventually it will, pneumonia won't.
I believe we all believe that our CLI and other trials will result in approvals, it's uncertain if we may get an approval for pneumonia first or not. It's been said that it's very possible an approval from regulators outside the U.S. may come in interim results, I believe we'll know more about that later this year. With these approvals, I would hope that most here agree that a market cap of a billion or more is justified. If our O/S, currently under 20 million remains under 25 million shares, a billion dollar market cap will have a share price of $40 or more.
Personally I believe over time a double digit billion dollar market cap is reasonable, especially if pneumonia is an authorized part of the mix, and perhaps it could be that high on the strength of pneumonia alone.
I certainly was not a fan of the reverse split we had previously, however, that said, it has been one that worked, it kept us on the Nasdaq and has us positioned for tremendous success. As I pointed out, a multi billion dollar market cap could lead to triple dollar share prices, the time may come when the company does splits to keep the share price at levels that people can afford.
Gary
Thanks,
Real World Data (RWD) is essentially what I've been saying for some time, get ours and others drugs in the hands of the Doctors and patient and see what works. Clinical trials are fine when you have years and hundreds of millions to spend, but RWD when you're facing a pandemic make sense as long as reputable companies with some preclinical knowledge of the products they're putting out take responsibility for what they're doing.
I believe we could get a vaccine much quicker if all the vaccine developers got together, and all received something based on their contribution in developing the final vaccine.
Gary
In yesterday's podcast I believe it was indicated that by July they looked to have production up to 25 units a month, and were working to grow 40% a month from there. I also think they indicated the U.S. would be served first.
My question would be, are they going to build the units intended to fill the U.K. order in the U.K., and if not, when do they intend to start shipping to the U.K. if U.S. orders are as high as their increasing rate of production.
I believe that as the financial records start to reflect the income they have coming in each month, the decimal point in the price will move two places to the right, if not by the end of this year, certainly by next.
Gary
I would hope that they're permitting a lot more compassionate use but are not saying so, perhaps because it might irritate agencies like the FDA. International regulators, not just our FDA, are moving faster than normal, but it still seems like it's a snails pace when compared with the speed in which coronavirus kills. I certainly don't know, but suspect the total numbers on ventilators around the world number into the hundreds of thousands, if they add all the patients in hospitals where their Doctor's believe the odds of patients requiring ventilators is at least 50% I suspect that the numbers might reach a million. I don't believe they'd have any problem at all trying PLX-PAD in 50K patients on ventilators, and 50K on patients believed approaching them. All that aren't receiving it would constitute being the control. Do that and in two to three weeks the benefits should be clear.
Gary
You may be right, and even if many hold to a few dollars they'll clearly have tremendous percentage gains, but the Institutions that buy their shares will have the greatest dollar gains. This is a pink because that's where it is today, it won't be there forever. It could move to the OTC shortly, perhaps the AMEX when it hits a buck, or hold on for $4 and reach the Nasdaq. Unless it's bought out, I believe it owns the sort of technology that's needed, and it should make it to the Nasdaq.
I believe the smarter investors here will at least keep some of their stock, personally, I'm not planning on selling any of my initial position, but I did increase that position some, and may trade that when it's substantially higher. I also believe that borrowing on margin can be smarter financially than taking a big capital gain on a highly appreciated stock. Of course I'd not consider it until the share price was stable and well over $7, but at that point the cost of a new Tesla would barely make a dent in my equity, and I believe margin interest is still deductible.
There is no doubt in my mind that coronavirus has been the catalyst for explosive growth in this stock, but as someone who's twice had catheters infected in hospitals, I know it's a problem that all hospitals are trying to avoid. I believe they're discovering what we have and as investors we're lucky enough to be at the right place at the right time.
Gary
If you have pneumonia, I'd suggest attempting to get compassionate use of PSTI's PLX-PAD, while it's only been in a few patients they've reported on to date, all appear to have improved. I believe all were on ventilators, so their families were actually who requested, or approved it, but it appears to be working well. Yes, I do hold the stock.
Gary
The question that certainly would be asked is, if the volume for the drug expanded dramatically by it's becoming part of the SOC for the treatment of pneumonia, would the price come down at all. Actually, even at that price if given prior to hospitalization, if it avoided many hospitalizations, and especially a lot of people being put on ventilators, it would be a substantial cost savings.
I still would like to hear of many more people getting the drug under compassionate use, or perhaps in some nations it's permitted to charge for the drug. Under right to try companies must provide cost information, which nearly all refuse to, in order to charge their production cost. If the FDA and others would settle on say 50% of list price, I believe a great deal of use could be made under right to try, or compassionate use, especially if insurance companies paid for drugs that offered the potential of saving them money in the long run.
I frankly have no idea if most insurance companies are paying for coronavirus coverage, or if Govt. funds are essentially paying all the bills. There is no doubt our National Debt, as well as the debt of most nations around the world will be up dramatically before this is over. Frankly I believe our National Worth is far greater than our National Debt, but people rarely look at an honest appraisal of what all the U.S., or any other nation for that matter, are worth.
I believe all around the world we practice accounting that depreciates all sorts of things that if you went to sell them actually appreciated dramatically.
Gary
I thought their statement in the podcast was very reasonable, they'll be doing some financing to enable them to expand, much won't be dilutive. They're talking about 40% month to month growth, that's huge. We just need to relax and let them do what they're doing.
If Vegas is serious about reopening, I wonder if casino's could continuously have our product misting to the point that say once every hour or two the entire casino was treated. That would be about as safe as I believe they could make it.
Gary
If they already have the vials being stored, how does that price compare with say conducting a clinical trial with 1000 patients that could result in an approval, say a year from now, perhaps less. I suspect that if it got the job done it would be cheaper than a formal trial, and much faster. Our FDA might not be happy about such an action, but I believe the pressure to do something would overcome their resistance.
Gary
If what's been said about PSTI having a substantial reserve of PLX-PAD in cryogenic storage is true, with a single placenta providing 20,000 doses, wouldn't it make sense to make 20K vials of the drug available for compassionate drug treatment throughout the world. Not a clinical trial, but so much anecdotal evidence that it cannot possibly be discounted.
The only requirement for those who receive it would be reporting the status of the patent receiving it before the drug was originally administered, and the outcome after the patient either returned to society, or was deceased.
I'm listening to the Mayor of Vegas attempting to make a case for reopening. It's been years since I spent time in Vegas, but I really don't know how a casino can be rendered safe in the midst of this threat. I know people will need to get back to work, but not until they can safely do so.
It would be a whole new ball game if our drug became the answer, and sufficient drug was available to use it at the first sign of pneumonia. If that were the case, and that proved effective, most patients could avoid hospitalization and coronavirus while highly infective wouldn't be nearly the danger. Then returning to a degree of normalcy could be safely done. I believe the company has, or can make sufficient doses to support such an effort, it would go into the millions of doses worldwide, but it should be possible.
Gary
Was there a new podcast, I linked on what I believed was, but it was clearly made before the U.K. announcement. If there is one, I'd both like a link, but also hope the moderators would link sticky it on the site.
Thanks,
Gary
I'm not big on conspiracy theories, but do I believe that BP would rather see companies like NWBO fail, sure. In the long run, I'm not sure it matters. Sure, with no firm news a concerted effort to hold down the share price can be somewhat successful, but what happens on solid, undenyable news.
I'll concede that bashers can find something in even the most positive news to create limited doubt, but when data screams this is worthy of approval, Investors and Institutions will realize what's about to happen, as will BP.
I can't say it will be Merck, even if they have the inside track, who'll say I want at least a part of this market. Their are so many BP's out there with billions to spend that a fight could certainly occur. While all of them would prefer to sell their mass produced pills and potions, I believe they also know that personalized drugs are the future, and if they want to maintain their piece of the pie, they need to get in. I can't think of anything that would benefit investors more than a bidding war to see who partners, or acquires NWBO.
As much as Merck seems to be interested, I've seen Roche get into many companies, in some cases first as a partner, then they acquire it, and then spin it out again, while maintaining a majority interest. Look at Genentech, currently wholly owned by Roche, but operating in a manner that they could spin it off again. Both investors and Roche have made money as they played this game. I certainly would rather see a partnership up front, then tremendous success as products reached the market. Finally if acquired it would be at a price that investors today don't even want to dream about, but if both DCVax-L and DCVax-Direct were approved and garnering a substantial market share, triple digit billion dollar market caps are not out of the question, so likewise they'd be what would be needed to buy out the company. Certainly this is at least 5 years out, perhaps longer, as DCVax-Direct needs some time, but if positive for multiple cancers, who can deny that much potential.
Gary
As I see it, the company said they were gathering the data, or more properly having their contractor do it. To me, that's not something you do if the SAP hasn't been accepted. While I'd have liked to see it expressed more clearly, I believe what they said was we're proceeding with all that's necessary to release TLD about the end of June. That's telling me that nothing else sits in their way, it's just a matter of getting it done.
Gary
I never turn down a green day, but frankly cannot believe how little value has thus far been placed on what happened last week. I don't know how long it will take before substantial U.K. purchases, or leases, show up on our books, but the totals from that contract will truly be something beautiful to behold. I don't know if they're going to set up to build much of the equipment in the U.K., I would be fine with that, though I'd be happier if it was build here and shipped there, but either way, it's money on our books.
Gary
I think the MM's are in strong control of the price right now, but doubt if they can hold on very long, but it may take something more directly from the company to break their hold. I suspect it won't be that long before Gary does a podcast, or puts out the Annual Report with a forecast that's based on the most recent occurrences, not simply where things stood on December 31, it may only be a verbal description of what's happening, but there will be lots of $$$$$$'s being discussed in that report.
Gary
I would hope that when we hear about the presentation the company's making in the next few days will indicate that they now have hundreds who've received the drug under compassionate use terms. Trials require formality, blinding, patients on placebo's, etc. and data may not be revealed for months. Compassionate use permits the results to be routinely reported on, it lets the world see what the drug is capable of, even if the medical experts don't like it, they cannot deny the benefits. I hope we've opened the door to all who'd like to save their lives, or that of someone in their family, as most on ventilators cannot make a conscious decision.
I'm fine if simultaneously clinical trials begin, but they'll take much longer even though the regulators are clearly acting far more dynamically then is the norm. I believe hundreds, or thousands who've received the drug under compassionate use terms will speak loads if the greater majority are clearly survivors.
Gary
I certainly cannot say the next time we'll hear from corporate management, but I believe when we do the message will be, we're making money, lots of it. They won't say it that way, but while it will be awhile before it shows up in quarterly reports, I believe by the time they report on this quarter, probably in early August, we'll be amazed at how much money they're bringing in.
I'd not be surprised if we get another podcast, after the news from the U.K., and it won't be that long before the Annual Report should hit. I believe they can take an extension on the first quarter, so that might be early June, but while Gary told us March was profitable, January and February weren't, so I expect a small loss. Our current quarter, and beyond should be game changers, and that's why I believe by end of the year we'll be over $1 and at least be on the OTC, or possibly even the AMEX.
Gary
As I see it, TLD is the end of the beginning. It certainly is a major goal, but there is a lot to do once it happens so the ultimate goal, approval can be achieved. On Saturday it certainly seemed that most who listened in were happy with the conference, though frankly few of our questions were answered. What was important was a commitment that the end was in sight, and for the most part we accepted that.
Based on the stock price, the market accepted it too, but not with a great deal of enthusiasm, that's fine, I believe it will build. In addition to the dates we think we'll get the TLD, it might be interesting to add what we believe the share price will be the day before TLD is announced. If that could be added, I'll guess at $.35 by then.
Out of curiosity, in that they are gathering data on patients, would all those remaining alive undergo complete examination so as to evaluate the likelihood they'd have at living dramatically longer, or will this be a simple verification that they're still alive. I would think in the end they'd want to know if a portion of those that still are alive are essentially in complete remissions, or categorized at some level below that.
Gary
6/29
Gary
If it were up to me, PSTI would make perhaps 1000 doses available at no cost all over the world on a compassionate use bases. The only requirement for each dose would be reporting the initial status of the patient, and an update of that status weekly into a database where all could see the outcome. Not nearly as controlled as a clinical trial, but a ton of anecdotal evidence of efficacy, if that's what it shows. All patients who gain access should be dealing with pneumonia that appears to be potentially headed toward a ventilator, or already be on a ventilator. My point is that such an effort should yield a great deal of information in under a months time as few if any patients outcomes won't be clear after a few weeks of receiving the drug.
We can get great results in 7 patients, or 70 patients, and people like Dr. Fauci will say we need clinical trials. Do it with 1000 patients and perhaps we stand a shot at the FDA saying, let's get this to everyone.
Gary
Unless Germany was working with PSTI's technology well before the announcement, and in volumes much greater than thought, it couldn't have that kind of impact. I would suspect that they tested more, and were better isolating, including the use of masks routinely.
50 of so years ago, when I did some work in Japan, it was quite common then to see people wearing masks. I was told that they were ill, and they were protecting others. My point is, they've recognized the benefits, while it was uncommon to see Americans who clearly don't feel well protecting others with such a practice. Hopefully this is changing, and now we're recognizing that masks can be of benefit for all at a time when people who feel perfectly healthy are actually spreading disease.
I believe I'm like many American's I know, I cannot tell anyone whether I've had a mild case of coronavirus, or not. I've had no fever, but have had a mild sore throat for a number of days, as had my wife. Without testing, I don't see how I can know if I've had it, or haven't. If I have, perhaps I now am protected, and won't be easily infected again, but of course if I haven't had it, as an immune compromised senior, I should remain isolated. Life would be far simpler if people could have a home test, rather like a pregnancy test, that could be delivered in the mail and wouldn't even require lab analysis. Barring that, testing should be available at drugstores, etc that were they type that gave the answer in 5 minutes. No other form of testing machine should be used, other than blood testing which could show if you ever had it. I don't know precisely what they're doing in Germany, but I'd be willing to bet they do a lot more testing. I also don't understand why in the beginning we didn't use the tests successfully developed by others, and fouled up badly in creating our own. I believe the U.S. does many things well, but it's fooling to ignore what's working in the rest of the world and insist on creating our own way of doing everything.
Gary
What do you believe the numbers should be. Should the O/S grow to 800 million or more, I still believe the case would be solid for the growth I'm suggesting. No company wants to use every authorized share they have available, I believe that if they went to 800 million they'd either want shareholders to authorize a lot more shares, say 1.5 billion, or at least a small reverse split, I'd rather authorize the additional shares.
This company can either become an industrial giant in this sector, or be bought out by a company that's big in the sanitizing area today. Personally I'd like to see it remain independent, but for enough billions, I'd be fine with such a buyout. Independently, I don't think it's currently possible to say just how high our market cap could go over say the next 5 or 10 years.
Gary
What they're doing may not be utilizing PSTI's technology, but I believe they'll learn they can benefit a few people with a single placenta, while PSTI can get 20,000 doses that produce similar benefits from a single placenta. I believe any benefits seen in Miami will lead to PSTI for much more massive dosing.
Gary
Britt,
I believe there is a step in between that's owned by Nasdaq, that's the AMEX and I believe $1 a share can qualify. While I believe that once we've hit $1 it won't be that much longer to $4, if I'm right it wouldn't be a bad move to move to the AMEX.
Personally, I've never like the dollar based qualification, it makes no sense to me that a company with a multi-billion dollar market cap doesn't qualify because their share price is still below $4, while a company with a tiny fraction of their market cap may qualify because they have so few shares outstanding. I really believe some market cap should be required to qualify, and perhaps about a quarter of that maintained to remain, but not based on a dollar price for the stock which typically encourages reverse splits to achieve, or remain on the Nasdaq. In very few cases have I seen a reverse split work, though PSTI did one to stay on the Nasdaq awhile ago, and it may work out well.
When people put down a company for too many shares outstanding I suggest they have a look at Apple, of course they were below a billion shares before they did a 7 for 1 split.
Gary
Even if dilutive financing takes the O/S up substantially, say to 700 million, $4 would represent a $2.8 billion dollar market cap. With a P/E of 10, earnings would need to be $280 million. I believe that with what's been announced just this week that won't be a problem within a year or so.
However, I don't really believe the company will be saying stop, we have all the sales we ever want. I believe the news is certainly going to attract more customers, and with each new customer others will see the benefits, and more customers will come. As this expands all over the U.K. do you suspect the French may see it, how about the Italians, etc.etc.etc.
I believe we're looking at the company that's changing sanitation, not just in hospitals, but in all sorts of places. If I'm right about this, either this will blow right through that $4 required for the Nasdaq and move up to well into double, or even triple digit billions, or at some point it will be bought out, and I'd be saddened if it weren't for at least double digit billions. Investors will be very well served, just give it a little time.
Gary